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SUMMARY  34 
 35 
HIV is a major risk factor for tuberculosis (TB) in latent TB infected (LTBI) subjects. This study was designed 36 
to determine if HIV infection of LTBI subjects compromises a balanced Mtb-specific Th17 response, of 37 
recognised importance in anti-TB immunity. Comparative analysis of Mtb and CMV-specific CD4+ T-cell 38 
responses using multiparameter flow cytometry demonstrates a selective and marked dampening of the 39 
Mtb-, but not CMV-specific response in LTBI subjects chronically infected with HIV. A significant loss of 40 
Mtb-specific CD4+ T-cell effectors expressing total IFN-γ, IL-2, TNF-α, MIP-1β and IL-17F as well as 41 
polyfunctional cells comprising upto 256 cell subsets was noted. Additionally, there was marked skewing 42 
of the Mtb-specific Th17 response with preservation of specific proinflammatory IFN-γ/IL-17 and significant 43 
loss of anti-inflammatory IL-10/IL-17 double positive effectors. This switch in Th17 profile restored by ART 44 
treatment was noted in chronic HIV-infected LTBI progressors but not LTBI long-term non-progressors. The 45 
HIV-driven impairment of Mtb-specific effectors cannot be attributed to selective HIV infection as cell-46 
associated HIV DNA and HIV RNA revealed equivalent viral burden in Mtb-, CMV- and HIV-specific CD4+ 47 
T effectors. We therefore propose that beyond HIV-induced loss of Mtb-specific CD4+ T-cells, the 48 
associated dysregulation of Mtb-specific T effector cell homeostasis can potentially enhance the onset of 49 
TB in LTBI subjects. 50 






AIDS and tuberculosis (TB) are among the top 10 leading causes of death worldwide. The interaction 54 
between the two causative pathogens, HIV and Mycobacterium tuberculosis (Mtb) exacerbates disease 55 
pathology and substantially contributes to this high incidence of mortality (Diedrich and Flynn, 2011). In 56 
2018, globally 38 million people were estimated to be HIV+, of which 862,000 were diagnosed as TB-57 
positive. Furthermore, TB is the leading cause of death among people with HIV accounting for one-third of 58 
HIV-related deaths i.e. 251,000 out of 770,000 people died from HIV-associated TB in 2018 (WHO TB 59 
Report 2019; UNAIDS Report 2019). Healthy subjects with latent TB infection (LTBI) are reportedly 60 
identified by the QuantiFERON® TB Gold In-tube Interferon Gamma Release Assay (IGRA) and commonly 61 
referred to as either LTBI or IGRA+ (henceforth referred to as IGRA+) (Auguste et al., 2017). Although the 62 
majority of IGRA+ subjects remain asymptomatic over their lifetime, 5-15% progress to active disease 63 
manifested either as pulmonary TB (PTB) in the lung or extrapulmonary TB (EPTB) in the lymph nodes, 64 
pleura, abdomen and other organs (Lin and Flynn, 2018). Chronic HIV infection enhances the risk of TB 65 
reactivation by >20-fold and annual incidence by 5-15% (Pawlowski et al., 2012; Bell and Noursadeghi, 66 
2018) that is reduced by 67% in ART-treated IGRA+ subjects (Lawn et al., 2015). On the other hand, 67 
increased incidence of TB in IGRA+ HIV-infected long-term non-progressors (LTNP), who are defined as 68 
remaining asymptomatic for at least seven years following infection with preserved CD4 T-cell counts 69 
despite being viremic and not on ART (Ciccone et al., 2011), has not been reported. Hence, deciphering 70 
the mechanisms by which HIV infection predisposes IGRA+ subjects to TB is an area of significant scientific 71 
and global health interest.  72 
Insight on immune mechanisms by which HIV may drive TB disease have emerged from both human 73 
studies and from non-human primate (NHP) models of HIV-TB coinfection. Reactivation of TB in NHP, is 74 
not likely solely governed by reduced CD4+ T-cell counts induced by HIV infection but depends on other 75 
immune factors, including macrophage disruption (Kuroda et al., 2018) and absence of granzyme-positive 76 
CD8+ T-cells (Foreman et al., 2016). Human studies, on the other hand, highlight both HIV-induced CD4+ 77 
T-cell depletion and functional changes of Mtb-specific CD4+ T-cells to be major factors by which HIV drives 78 
TB incidence (Douek et al., 2003; Geldmacher et al., 2010; Okoye and Picker, 2013; Esmail et al., 79 
2018; Murray et al., 2018; Amelio et al., 2019). Understanding the precise functional changes that HIV 80 




and functional studies highlight selective vulnerability of Mtb-specific CD4+ T-cells to HIV infection. Effector 82 
memory CD4+ T-cells that express the HIV entry receptor CCR5, are dramatically depleted in the gut which 83 
serve as a major in vivo reservoir of infection (Yang et al., 2012). Importantly, CD4+ memory T-cells primed 84 
to recognize Mtb and HIV antigens express elevated levels of HIV entry coreceptor, CCR5, and conversely 85 
low in the anti-HIV chemokine, MIP-1β, which binds CCR5 and blocks HIV entry; these cells are 86 
consequently highly susceptible to HIV infection, whereas memory cells specific for CMV, an opportunistic 87 
pathogen that emerges late in HIV infection, are poorly infected linked to high MIP-1β expression and lower 88 
CCR5 expression (Geldmacher et al., 2010; Geldmacher et al., 2012; Bronke et al., 2005). Moreover, 89 
Mtb-specific CD4+ T-cells display an early differentiated phenotype with enhanced proliferation potential 90 
due to higher IL-2 production making them more permissive to HIV infection than the terminally 91 
differentiated CMV-specific CD4+ T-cells (Ahmed et al., 2016). Additionally, cytokine imbalance and loss 92 
of polyfunctional Mtb-specific CD4+ T-cells is also associated with HIV-infected IGRA status (Amelio et al., 93 
2019; Day et al., 2008; Riou et al., 2016; Day et al., 2017).  94 
Within the CD4 compartment, a major focus is to understand how HIV alters the Mtb-specific Th17 95 
responses based on substantial recent evidence highlighting CD4+ Th17 cells, which otherwise are 96 
important in maintaining gut mucosa integrity, to play crucial roles in protective immunity against HIV and 97 
Mtb infection (Esmail et al., 2018). Th17 cells exhibit considerable heterogeneity and plasticity as they can 98 
differentiate into distinct subsets in the presence of specific cytokine milieu. Naive CD4+ T-cells cultured in 99 
the presence of TGF-β and IL-6 differentiate into regulatory and protective Th17 that co-express of IL-17 100 
and IL-10, while the additional presence of IL-1β and/or IL-23 steers them toward the pro-inflammatory and 101 
pathogenic Th17 cells that co-express of IL-17 and IFN-γ (Mercer et al., 2014). Moreover, Mtb-specific 102 
memory cells in IGRA+ subjects are mostly contained within the CXCR3+CCR6+ CD4+ T-cell subset that 103 
express both IFN-γ and IL-17 and represent the pathogenic phenotype (Acosta-Rodriguez et al., 2007). 104 
Further, CCR4+CCR6+ Th17 and CXCR3+CCR6+ (Th1/Th17) cells that express the HIV coreceptors CCR5 105 
and CXCR4 and secrete low levels of MIP-1β are highly susceptible to in vitro infection by R5 and X4 HIV 106 
viruses (Elhed et al., 2010; Gosselin et al., 2010). Additionally, these Th17 subsets also exhibit gut- and 107 
lymph node-homing potential that might relate to their significant depletion in the gastrointestinal tract of 108 
chronic HIV-infected individuals (Bixler and Mattapallil, 2013), but not in HIV-infected LTNP (Ciccone et 109 




Data from our laboratory has provided the first evidence of the potential importance of a balanced Mtb-111 
specific Th17 response in TB immunity. We demonstrated the presence of Mtb-specific regulatory or anti-112 
inflammatory IL-17+ cells that co-expressed IL-10 in IGRA+ subjects, whilst subjects with TB disease 113 
showed significant loss of this subset whilst preserving Mtb-specific proinflammatory IL-17+ cells that co-114 
expressed IFN-γ (Rakshit et al., 2017). Additionally, sterile granulomas in a TB NHP model were 115 
associated with increased T-cells producing both IL-10 and IL-17 (Gideon et al., 2015). Importantly, 116 
protective immunity to Mtb infection induced by BCG vaccination in a live challenge NHP model was 117 
associated with IL-10 and Mtb-specific Th17 CD4+ T-cells (Dijkman et al., 2019). In our recent study 118 
involving young human adults, we showed that BCG revaccination has the potential to enhance Mtb-119 
specific IL-17+ cells that co-expressed IL-10 but not IL-17+ cells that co-expressed IFN-γ (Rakshit et al., 120 
2019). The aim of this study was therefore to investigate the impact of HIV infection on the nature of the 121 
Mtb-specific Th17 response. We hypothesized that HIV infection of IGRA+ subjects would alter the balance 122 
of Mtb-specific Th17 pro- vs anti-inflammatory IL-17+ cells, skewing the response to a proinflammatory 123 
phenotype previously noted in subjects with TB disease (Rakshit et al., 2017), thereby potentially 124 
predisposing IGRA+ subjects to TB disease progression. We provide evidence in support of our hypothesis 125 
through a comparative analysis of immune profiles combined with HIV load analyses in CD4+ T-cells 126 
specific for Mtb vs. CMV in IGRA+ subjects with progressive HIV disease vs. HIV+IGRA+ long-term non-127 
progressors (LTNP) and subjects with TB with and without chronic HIV infection before and after ART or 128 
ATT treatment.   129 






HIV infection significantly reduces the absolute numbers of total Mtb-specific CD4+ T-cells in IGRA+ 133 
individuals 134 
 135 
HIV Infection leads to the functional impairment of Mtb-Specific CD4+ and CD8+ T-cell responses (Amelio 136 
et al., 2019); however, the precise mechanisms by which HIV hampers the Mtb-specific CD4+ T-cell 137 
response is poorly understood To address this issue, we first compared the absolute numbers of Mtb-138 
specific CD4+ T-cells in subjects from the following four clinical groups: HIV+IGRA+ versus HIV-IGRA+ and 139 
HIV+IGRA- versus HIV-IGRA-, with all HIV+ subjects displaying significantly lower absolute CD4 T-cell 140 
counts than the HIV-uninfected counterpart group (see Table 1). Representative FACS plots depicting the 141 
complete stepwise gating strategy to identify functional subsets is shown in Figure S1. Comparison of HIV-142 
IGRA+ versus HIV+IGRA+ subjects (green versus red scatter plots) would assess the impact of chronic HIV 143 
infection on Mtb-specific responses of IGRA+ subjects, whilst a comparison of HIV-IGRA- versus HIV+IGRA- 144 
subjects (brown versus blue scatter plots) would determine the impact of chronic HIV infection independent 145 
of IGRA status (Figures 1A and 1B). We measured the expression of 6 key effector cytokines, namely 146 
IFN-γ, IL-2, MIP-1β, TNF-α, IL-10 and IL-17F in response to the Mtb ESAT6/CFP10 fusion protein referred 147 
to as EC- and to a pool of 4 Mtb DosR latency antigens (Rv1733c, Rv1737c, Rv2029 and Rv2628), referred 148 
to as LT Ag in CD4+ Tcells. These antigens were selected based on previous studies showing responses 149 
to the LT Ag in particular to clearly distinguish asymptomatic IGRA+ subjects from those with active TB 150 
disease (Rakshit et al., 2017; Coppola and Ottenhoff, 2018). To determine if HIV infection impacted 151 
recall responses, we compared the Mtb-specific response with that of CMV. Unlike TB, which is evident at 152 
all stages of HIV infection, CMV emerges late in HIV infection as an opportunistic pathogen concomitant 153 
with profound CD4+ T-cell loss. Mitogen driven (PHA) responses were measured to evaluate the impact on 154 
global T-cell responses, irrespective of cell specificity. Representative flow cytometry plots depict effector 155 
cytokine expression by CD4+ T-cells to different antigenic stimuli relative to unstimulated negative control 156 
(Figure S2). 157 
Figure S3 show the total frequencies of cytokine positive CD4+ T-cells enumerated and in Figures 1A and 158 
1B, the same data is represented as absolute CD4+ numbers corrected for individual donors’ CD4+ T-cell 159 




variations in their circulating CD4+ T-cell numbers (see Table 1). We record significant reduction in all 161 
cytokine subsets specific for both EC and LT Ag in HIV+IGRA+ (red) versus HIV-IGRA+ (green), with the 162 
exception of IL-10 (Figure 1A). Consistent with lower or minimal Mtb antigenic burden in IGRA- compared 163 
to IGRA+ subjects (Carpenter et al., 2015), the IGRA- groups, HIV+ (blue) and HIV- (brown) on the whole 164 
had lower absolute numbers of these Mtb-specific CD4+ T-cells compared to their IGRA+ counterparts (red 165 
and green), (Figures 1A and 1B). Except for TNF-α, the downward trend noticed in the absolute numbers 166 
of most cytokines to EC stimulation did not reach statistical significance; neither were there any appreciable 167 
differences in absolute numbers of cytokines to LT Ag stimulation in HIV+IGRA- compared to HIV-IGRA- 168 
subjects (Figure 1B). In keeping with previous data (Geldmacher et al., 2010), a marked 10-fold reduction 169 
in MIP-1β was noted in Mtb-specific cells from the IGRA+ group, whereas an increase in the absolute 170 
numbers of MIP-1β+ CMV-specific CD4+ T-cells was observed in IGRA- subjects following HIV infection 171 
(Figures 1A and 1B). With the exception of MIP-1β, all other effector cytokine responses measured to 172 
CMV and PHA stimulation were similar across all subjects tested, providing strong evidence that HIV 173 
infection had the potential to selectively impair Mtb-specific recall responses in IGRA+ subjects (Figures 174 
1A and 1B). These changes observed in absolute numbers of effector cytokine-positive CD4+ T-cells 175 
concurred with changes in cytokine frequencies (see Figure S3). We also evaluated the impact of HIV 176 
infection on Mtb-specific CD8+ T-cell responses. Figure S4 shows no significant differences in the total 177 
frequencies of Mtb-specific CD8+ T-cells expressing IFN-γ and TNF-α in HIV-uninfected versus -infected 178 
subjects. However, absolute numbers of EC-specific CD8+ T-cells expressing IFN-γ in HIV+IGRA+ and the 179 
LT Ag-specific CD8+ T-cells expressing TNF-α in HIV+IGRA- were significantly enhanced compared to their 180 
respective HIV- counterparts (Figure S4). Our CD8 data is broadly consistent with other human studies 181 
showing no significant changes in frequencies of EC-specific CD8+IFN-γ+ T-cells in HIV-infected individuals 182 
irrespective of IGRA status or CD4 T-cell counts (Murray et al. 2018, Kalokhe AS et al. 2015) with the 183 
increase in absolute number of cytokine-positive CD8+ T-cells in HIV+IGRA+ subjects (Figure S4), likely 184 
due to the recognised HIV-infection induced increase in blood CD8 T-cell counts (Chiacchio et al. 2018). 185 
The absolute numbers of CMV-specific total IFN-γ+ and TNF-α+ CD4+ and CD8+ T-cells, for all study 186 
participants has been provided in Figure S5. Consistent with previous reports showing CMV recall 187 
responses to be well preserved (Chiacchio et al. 2018; Murray et al. 2018), we demonstrate a high 188 
proportion of CMV-specific CD4+ (100%) and CD8+ (80-90%) T-cell responders in the subjects recruited to 189 




HIV infection reduces the polyfunctional Mtb-specific response of IGRA+ subjects  191 
 192 
Mtb-specific, central memory polyfunctional responses are an important hallmark of IGRA+ subjects 193 
(Rakshit et al., 2017; Arroyo et al., 2016) and can be impaired by HIV infection (Day et al., 2017; Diedrich 194 
and Flynn, 2011). We therefore evaluated the differences in polyfunctional CD4+ T-cell responses between 195 
HIV-IGRA+ versus HIV+IGRA+ subjects using a panel of 8 key effector cytokines (IFN-γ, IL-2, TNF-α, MIP-196 
1β, IL-10, IL-17A, IL-17F and IL-22). Polyfunctionality was determined by analysing all 256 different 197 
combinations of these 8 cytokines stratified using the Boolean gating strategy in FlowJo and employing 198 
COMbinatorial Polyfunctionality Analysis of Antigen-Specific T-cell Subsets (COMPASS) (Lin et al., 2015), 199 
an advanced bioinformatics software to derive polyfunctional scores (PFS) (Figure 2A). Differences in PFS 200 
between groups were estimated through a linear model fit to the PFS for each antigen (see STAR Methods). 201 
After multiple testing adjustments, significant reduction was observed in the CD4+ T-cell polyfunctional 202 
response to LT Ag stimulation and a trend for EC in HIV+IGRA+ compared to that of HIV-IGRA+ subjects 203 
(Figure 2A). Further, consistent with the total cytokine data in Figure 1, the polyfunctional response in 204 
IGRA- subjects, was significantly lower than that of IGRA+ subjects. In-depth visualisation of immune 205 
subsets simultaneously expressing one, two, three, four and five combinations of cytokines are illustrated 206 
as heatmaps in Figure S6, with a detailed explanation included in the supplementary file (results section). 207 
The polyfunctional CD4+ T-cell response was further probed by analysis of the above data (Figure 2A) in 208 
Simplified Presentation of Incredibly Complex Evaluations (SPICE) (Roederer et al., 2011). Using this 209 
software, the global cytokine profile induced in IGRA+ subjects to EC and LT Ag stimulation represented as 210 
pie charts in Figure 2B were functionally similar but each of these responses were profoundly impacted by 211 
HIV infection (Figure 2B). This analysis clearly demonstrates the striking loss of single MIP-1β+ cells 212 
(shown as blue arcs) and the EC-specific double-positive TNF-α+MIP-1β+ subset but an increase of single 213 
TNF-α+ cells (shown as purple arcs) in all HIV+ subjects independent of IGRA status (Figure 2B). In 214 
addition, this analysis revealed that HIV reduces many combinations of 2+, 3+, 4+ and 5+ cells whilst 215 
preserving single-positive IFN-γ, IL-2, IL-17F and IL-10 cells in HIV+IGRA+ and HIV+IGRA- compared to 216 
HIV-IGRA+ subjects, thereby indicating an overall impairment of polyfunctional responses in HIV+ subjects 217 
(Figure 2B). Taken together, our data demonstrate that CD4+ T-cell polyfunctional responses are markedly 218 





HIV infection skews the balanced Mtb-specific Th17 response in IGRA+ subjects 221 
 222 
Previously we have shown that a balanced Mtb-specific Th17 response comprising both IL-17+IFN-γ+ pro-223 
inflammatory and IL-17+IL-10+ anti-inflammatory effectors to be a hallmark of HIV-IGRA+ individuals 224 
(Rakshit et al., 2017). Therefore, we sought to evaluate the status of the Th17 response in IGRA+ subjects 225 
following HIV infection. Using COMPASS, we conducted a detailed analysis of the probability of EC and LT 226 
Ag-specific CD4+ Th17 cells for each subject averaged across selected functional profiles for either IFN-γ 227 
or IL-10 together with all combinations of IL-17A, IL-17F and IL-22 (Figure 3A). HIV+IGRA+ and HIV+IGRA- 228 
subjects had significantly fewer LT Ag-specific regulatory CD4+ Th17 subsets co-expressing IL-10 with IL-229 
17A/IL-17F/IL-22, whereas the reduction of these subsets was not statistically significant for EC-specific 230 
cells, indicating that the LT Ag-specific Th17 response was more significantly impacted by HIV infection 231 
compared to the EC response (Figure 3A).  232 
To further interrogate the above data, we used SPICE to identify the precise Mtb-specific Th17 subsets that 233 
were altered by HIV infection by separately enumerating the absolute numbers of three combinations of 234 
double-positive pro-inflammatory (IFN-γ+IL-17A+; IFN-γ+IL-17F+ and IFN-γ+IL-22+) and three combinations 235 
of double-positive anti-inflammatory or regulatory (IL-10+IL-17A+; IL-10+IL-17F+ and IL-10+IL-22+) Th17 cell 236 
subsets (see methods), with representative FACS profiles shown in Figure S7. In Figure 3B, we 237 
demonstrate the impact of HIV infection on each of these six subsets in IGRA+ subjects. We highlight the 238 
following salient points: (i) Absolute CD4+ T-cell numbers of all three EC- and LT Ag-specific regulatory 239 
Th17 subsets co-expressing IL-10, which form a minor but distinct viable cell population as confirmed by 240 
back gating analysis (Figure S8), is significantly lower in HIV+IGRA+ versus HIV-IGRA+ subjects (Figure 241 
3B). (ii) Although IFN-γ+IL-17A+ and IFN-γ+IL-22+ subsets were significantly reduced by HIV infection 242 
noticeably to LT Ag but not to EC stimulation, the absolute numbers of these pro-inflammatory subsets 243 
were relatively higher than the IL-10+ regulatory subsets, suggesting that regulatory subsets are impacted 244 
to a greater extent upon HIV infection (Figure 3B).  245 
Next, we conducted a detailed analysis of HIV infection on Mtb-specific Th17 subsets across seven different 246 
clinical groups where Th17 cells were grouped into pro-inflammatory (IFN-γ expression with either IL-247 
17A/IL-17F or IL-22) or anti-inflammatory (IL-10 expression with either IL-17A/IL-17F or IL-22) subsets. In 248 
addition, we probed the impact of HIV infection on IFN-γ +IL-10+ cells, another anti-inflammatory regulatory 249 




Figure 3C shows these three subset comparisons in IGRA+ and IGRA- HIV+ progressors; IGRA+ HIV+ long 251 
term non-progressors; HIV+ subjects with TB and HIV uninfected IGRA+, IGRA- and TB+ subjects serving 252 
as controls. Absolute numbers of cytokine positive cells corrected for multiple comparisons across these 253 
seven clinical groups is shown in Figure 3C, with salient observations as follows: (i) Most HIV-IGRA- 254 
subjects (brown) lacked EC and LT Ag-specific pro-inflammatory IFN-γ+ Th17 cells but had low absolute 255 
numbers (less than 0.1%) of IL-10+ regulatory Th17 cells. (ii) Notably, HIV infection of IGRA- subjects 256 
enhanced the pro-inflammatory Th17 subset (blue). (iii) Compared to HIV-IGRA- subjects, HIV-IGRA+ 257 
subjects (green) had a greater LT Ag- and EC-specific Th17 response (0.1% and greater), with HIV infection 258 
inducing dramatic loss of regulatory IL-10+ Th17 subsets (red). (iv) A comparison of IGRA+ HIV+ progressors 259 
who had low CD4 T-cell counts with those of IGRA+ HIV+ long term non-progressors (LTNP) with preserved 260 
CD4 T-cell counts showed that LTNPs have mainly regulatory Th17 subsets with low proportion of pro-261 
inflammatory IFN-γ+ Th17 subsets (magenta). (v) The data also highlights that HIV negative subjects with 262 
TB disease (black) to have the highest numbers of pro-inflammatory IFN-γ+ Th17 cells compared to any 263 
other group  with few regulatory IL-10+IL-17+ cells, however HIV infection in TB+ subjects leads to a further 264 
decrease in both regulatory as well as pro-inflammatory Th17 subsets (dark grey). (vi) Furthermore, we 265 
demonstrate that IFN-γ+IL-10+ cells are present in HIV-IGRA+ and HIV+IGRA+LTNP subjects but low in 266 
HIV+IGRA+ and HIV+TB+ groups. Taken together these data provide strong evidence that HIV infection 267 
significantly impacts the balance between pro- and anti-inflammatory Mtb-specific Th17 subsets with 268 
significant dysregulation of the Mtb-specific regulatory Th17 cells co-expressing IL-10 following chronic HIV 269 
infection of IGRA+ subjects.  270 
 271 
Anti-retroviral (ART) and anti-TB (ATT) therapies enhance Mtb-specific total cytokine effector 272 
responses 273 
 274 
ART and ATT have been shown to increase the absolute numbers of Mtb-specific CD4+ T-cells in HIV-275 
IGRA+ subjects (Chiacchio et al., 2018). We sought to investigate whether ART and ATT can restore Mtb-276 
specific cytokine responses impacted by HIV and Mtb infection respectively through a longitudinal analysis 277 
of samples taken pre and 1-year post treatment. ART increased the CD4 T-cell count in all IGRA+ subjects 278 
tested (Supplementary Clinical File 1). In addition, the absolute numbers of total LT Ag- and EC-specific IL-279 




(Figure 4A). ATT treatment of HIV-uninfected subjects with TB also highlighted significant enhancement 281 
of IL-10+ LT Ag- and EC-specific and MIP-1β+ LT Ag-specific CD4+ T-cells; all other effectors were however 282 
not altered (Figure 4B). Therefore, ART treatment of HIV+IGRA+ subjects enhanced a broad range of total 283 
Mtb-specific T-cell effectors, whilst ATT treatment led to partial restoration of cytokine responses in HIV-284 
uninfected subjects with TB. To note: ATT treatment of IGRA+ subjects could not be conducted as ATT is 285 
only given to subjects with full blown TB in India. 286 
 287 
ART and ATT restore regulatory Th17 responses in HIV+ and TB patients 288 
 289 
We next examined whether ART can specifically restore the skewed Mtb-specific Th17 response induced 290 
by HIV infection, and if ATT can restore these responses in TB treated patients. We observed that ART 291 
significantly reduced the absolute numbers of proinflammatory IFN-γ+Th17 subsets and conversely 292 
increased regulatory IL-10+Th17 subsets in response to both EC and LT Ag stimulation (Figure 5A). ATT 293 
also significantly enhanced absolute numbers of LT-Ag specific IL-10+IL-17A+, IL-10+IL-17F+ and IL-10+IL-294 
22+ and EC-specific IL-10+ IL-17F+ Th17 subsets and conversely, a trend was noted for ATT treatment to 295 
suppress EC-specific IL-17F and IL-22 but not IL-17A cells that co-expressed IFN-γ (Figure 5B). In 296 
conclusion, both ART and ATT have the potential to restore the Mtb-specific regulatory Th17 response with 297 
ART also effective in dampening the Mtb-specific pro-inflammatory Th17 response in HIV-infected IGRA+ 298 
subjects. 299 
 300 
Loss of Mtb-specific effector cells in HIV-infected IGRA+ subjects is not due to selective HIV 301 
infection associated with reduced expression of the anti-HIV chemokine, MIP-1β.  302 
 303 
We next assessed if the selective early loss of Mtb-specific effectors in HIV+IGRA+ subjects, as shown in 304 
Figure 1, was due to higher HIV infection levels and associated absence of anti-HIV chemokine, MIP-1β 305 
expression by probing the viral load of antigen-specific CD4+ T-cells that expressed high (CMV-specific) 306 
versus low levels (Mtb-specific) of MIP-1β. The CD4 count and viral loads of the subjects used for this 307 
analysis are shown in Figure S9. To note: all HIV+ subjects with chronic HIV infection recruited to this study 308 
went on to subsequent ART treatment due to a declining CD4 T-cell count. An overview protocol used to 309 




induced expression of CD154 and CD69 to capture specific cells as reported previously (Bacher, et al., 311 
2013). Both CD154+CD69+ (antigen-specific activated) and CD154-CD69- (un-activated control) memory 312 
(CD45RA-) CD4 T-cells were captured by flow cytometry-based cell sorting after stimulation of PBMCs with 313 
Mtb antigens (EC or LT Ag) or with HIV-PTE (Env and Gag) or with CMVpp65 peptides. To verify the 314 
capture and stimulation efficacy, we first confirmed by qRT-PCR that the antigen activated subsets in each 315 
case expressed higher levels of IL-2 and IFN-γ, key cytokines induced by T-cell activation. For each antigen 316 
stimulation, we demonstrate that the CD154+CD69+ subset expressed significantly higher IFN-γ and IL-2 317 
mRNA than the CD154-CD69- counterpart (Figures 6B and 6C). We also demonstrate that Mtb-specific 318 
CD154+CD69+ cells do not express higher MIP-1β than their CD154-CD69- counterpart, whereas CMV-319 
specific cells did (Figure 6D). This qRT-PCR data complements the data in Figure 1 and confirms the 320 
captured Mtb-specific cells to be MIP-1βlow relative to the captured CMV-specific cells.  321 
Figure 7 provides the viral load data on the captured antigen specific cells. To quantify HIV DNA copy 322 
number, a standard curve was first optimized to detect as low as 1 copy of CD3 (reference gene) and HIV-323 
1 LTR (Figure S10); the qPCR assay was sensitive for 6 copies of CD3 gene and 3 copies of HIV-1 LTR 324 
gene with 100% confidence as determined by testing genomic DNA isolated from ACH2 cells. After cut-off 325 
to exclude non-specific signals from low HIV-1 DNA loads (cut-off HIV-1 LTR gene qRT-PCR Signal Ct=30) 326 
and correlation of cell counts, the HIV-1 DNA copy number did not significantly vary in CD154+CD69+ T-327 
cells across different antigen specificities (Figure 7A). Antigen stimulation in the absence of ART for 16 hr 328 
is recognised to be a weak stimulus for new HIV DNA synthesis; consistent with this, we show no significant 329 
difference in HIV DNA load between the CD154+CD69+ and it’s the CD154-CD69- counterpart in Mtb and 330 
HIV-specific cells; however there was a weak induction of HIV DNA in CMV-stimulated cells (Figure 7B).   331 
Cell associated HIV RNA was simultaneously quantified in each population by calculating the Fold Change 332 
(FC) of GAG gene expression in the CD154+CD69+ and the CD154-CD69- counterpart relative to a negative 333 
control cell culture not exposed to any antigen. There was no significant difference in HIV RNA levels 334 
between CD154+CD69+ cells of different antigen specificities (Figure 7C). In addition, the HIV RNA levels 335 
in CD154+CD69+ versus CD154-CD69- cells did not differ significantly, indicating no new burst of HIV Gag 336 
DNA translation following antigen stimulation (Figure 7D). We can confirm that this lack of induction of cell 337 
associated HIV RNA and HIV DNA at 16 hr post antigen stimulation was not due to inefficient activation as 338 
all antigens induced IFN-γ and IL-2 significantly in the CD154+CD69+ compared to the CD154-CD69- 339 




T-cells stimulated with HIV PTE pool exhibited a higher proportion (41%) of cell associated HIV RNA 341 
compared to Mtb- and CMV-specific cells or total memory cells. Therefore, we provide strong evidence that 342 
HIV does not exclusively infect MIP-1βlow Mtb-specific cells from IGRA+ subjects with chronic HIV infection 343 
since equivalent viral burden were detected in MIP-1βhi CMV-specific T-cells from the same subjects. In 344 
summary, MIP-1β levels do not seem to govern in vivo HIV infection levels of antigen-specific CD4+ T-cell 345 




DISCUSSION  347 
 348 
This study provides fresh insights into the impact of HIV infection on the nature of the Mtb-specific CD4+ T-349 
cell response, particularly the Th17 response and unravels probable mechanisms that underpin why HIV 350 
infection is known to predispose IGRA+ subjects to active TB, a topic of recognised global health 351 
importance.The increased vulnerability of Mtb-specific CD4+ T-cells to HIV infection due to low MIP-1β 352 
expression is an attractive hypothesis for explaining why HIV selectively reduces the frequencies of Mtb-353 
specific MIP-1βlow effectors whilst preserving MIP-1βhi CMV-specific CD4+ T-cell effectors (see 354 
Geldmacher et al, 2010). In keeping with previous data (Amelio et al., 2019; Diedrich and Flynn, 2011; 355 
Murray et al., 2018), we confirm that HIV infection of IGRA+ subjects selectively impairs Mtb-specific CD4+ 356 
T-cell effectors expressing several key cytokines, including IFN-γ, IL-2, TNF-α, MIP-1β, IL-17 and IL-10 357 
whilst preserving recall responses to CMV.  Additionally, in this study we report that MIP-1βlow Mtb-specific 358 
cells isolated from HIV-infected IGRA+ subjects harboured similar viral load compared to MIP-1βhi CMV-359 
specific cells. A critical explanation for this lack of concurrence between our viral load data and those of 360 
Geldmacher et al, may be linked to significant differences in the clinical stage of HIV-infected subjects 361 
studied. Geldmacher et al measured viral load in Mtb-specific and CMV-specific cells isolated from IGRA+ 362 
subjects in the acute phase of HIV infection, before persistent loss of peripheral CD4 T-cell counts had 363 
occurred whereas we studied IGRA+ subjects with chronic HIV infection with significantly lower CD4 T-cell 364 
counts than uninfected controls (see Table 1). We contend that in the scenario of rising viral load and 365 
declining CD4+ counts as in the case of patients we studied, MIP-1β expression in CD4+ T-cells is less 366 
critical in setting a threshold for HIV infection and instead maybe driven by chronic T-cell activation.  367 
HIV-mediated functional impairment of Mtb-specific CD4+ T-cell immune responses may also contribute to 368 
erosion of anti-TB immunity and thereby predispose IGRA+ subjects to TB (Esmail et al., 2018). Several 369 
studies have investigated the quality of Mtb-specific CD4+ T-cell response in the context of HIV infection 370 
and reported a steady deterioration in the polyfunctionality of CD4+ T-cells (Day et al., 2017; Murray et al., 371 
2018).  Likewise, we too observed significant impairment of the overall polyfunctional CD4+ T-cell response 372 
especially to LT Ag in HIV+IGRA+ subjects, which was restored following ART. Beyond polyfunctionality, 373 
there is particular interest in understanding how HIV infection impacts Mtb-specific Th17 responses given 374 
their increasing importance in anti-TB immunity (Rakshit et al., 2017, Rakshit et al., 2019; Dijkman et al., 375 




significantly reduces the frequency of Mtb-specific IL-10 and IL-17 co-expressing CD4+ T-cells in IGRA+ 377 
subjects. Understanding how HIV infection induces loss of IL-17+IL-10+ is important. One mechanism may 378 
be linked to the efficient replication of HIV in Th17 cells in the gut (Bixler and Mattapallil, 2013). Gut-379 
homing CXCR3+CCR6+CD4+ Th1/Th17 cells with increased TNF-α/IL-10 ratio are reportedly highly 380 
permissive to HIV infection (Gosselin et al., 2010; Alvarez et al., 2013). Moreover, HIV is thought to 381 
preferentially replicate in naïve precursors of regulatory Th17 cells that could possibly lead to distorted 382 
polarization of Th17 cells towards the pathogenic phenotype in the presence of inflammatory environment 383 
in the gut (DaFonseca et al., 2015). We therefore propose that by reducing the frequencies of anti-384 
inflammatory IL-10+Th17 cells whilst sparing pathogenic IFN-γ+Th17 cells, HIV creates a niche for 385 
persistent replication. Further, the nature of HIV infection clearly influences the changes induced in the 386 
Th17 response. Thus, LTNP subjects with a stable CD4 count in contrast to HIV+IGRA+ progressors, had 387 
a robust Mtb-specific Th17 response that included largely anti-inflammatory IL-10+IL-17+ cells and few pro-388 
inflammatory IFN-γ+IL-17+ cells. ART treatment of chronic HIV-infected IGRA+ progressors restored their 389 
Mtb-specific responses, including polyfunctional cells and IL-10+IL-17+ anti-inflammatory cells, thus 390 
confirming HIV infection to be a major driver of these immune changes.  391 
Additional key mechanisms by which HIV may alter the balance of IL-10+ and IFN-γ+ Th17 subsets maybe 392 
linked to HIV-driven changes in cytokines that are known to drive Th17 cell differentiation. A combination 393 
of several factors involving lineage-specific polarizing cytokines like IL-23, IL-1β as well as IL-2, CCR6, 394 
signaling mediators, transcription factors, metabolism, glucocorticoids, etc., are known to act in synergy to 395 
regulate the Th17/Treg balance and inter-Th17 subset balance (Yang et al., 2016; Seki and Nishizaw, 396 
2016). Interestingly in the context of TB, Th17 cells polarized under a hypoxic environment secrete IL-10 in 397 
the TB granuloma (Volchenkov et al., 2017). Moreover, the paucity of the phenotypically naive CD4+ T-398 
cell subsets, nTregs and CD25+CD127+FoxP3− enriched in Th17-lineage committed cells has been 399 
associated with greater permissiveness to abortive and/or integrative HIV infection and maybe a potential 400 
mechanism contributing to Th17 deficiency in HIV-infected subjects (Gosselin et al., 2010). Taken 401 
together, limited expression of Th17-specific growth factors (e.g., IL-21, TGF-β) required for differentiation 402 
and maintenance of regulatory Th17 cells in the inflammatory scenario of the HIV-infected gut may 403 
contribute to the loss of Mtb-specific IL-17+IL-10+ cells in IGRA+ subjects with chronic HIV infection.    404 
To summarize, we provide first evidence that HIV infection disrupts the Mtb-specific Th17 response by 405 




can be restored by ART. In addition, our data indicates that HIV skews the Mtb-specific Th17 response 407 
towards a pro-inflammatory profile in chronic IGRA+ progressors, a pathogenic signature that is 408 
characteristic of subjects with active TB, whereas the Mtb-specific regulatory Th17 response is retained in 409 
HIV-infected IGRA+ LTNP. Further analysis of HIV infection in Th17 subsets is warranted. Interestingly, our 410 
results corroborate recent findings that show antibody-induced CD4+ T-cell depletion alone is insufficient to 411 
trigger the onset of TB in macaques with latent TB in the absence of HIV infection (Bucsan et al., 2019). 412 
Further, chronically SIV-infected macaques with latent Mtb infection that eventually progressed to TB 413 
displayed enhanced immune activation, inflammation and distorted CD4+ T-cell differentiation phenotypes 414 
compared to macaques that did not progress to TB even though both groups had undergone massive SIV-415 
induced CD4+ T-cell depletion (Bucsan et al., 2019). Therefore, HIV-induced preferential loss of Mtb-416 
specific IL-10+ regulatory CD4+ Th17 cells may be detrimental to the host because a balanced immune 417 
response is likely crucial for Mtb containment. 418 
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STAR METHODS 440 
 441 
KEY RESOURCES TABLE 442 
 443 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
V450 Mouse Anti-Human IFN-γ BD Biosciences Cat# 560371 Clone: B27 
FITC Mouse Anti-Human TNF BD Biosciences Cat# 552889 Clone: MAb11 
Alexa Fluor 700 anti-human IL-2 BioLegend Cat# 500320 Clone: MQ1-17H12 
Brilliant Violet 605 anti-human IL-17A BioLegend Cat# 512326 Clone: BL168 
Brilliant Violet 650 Mouse Anti-Human IL-17F BD Biosciences Cat# 564264 Clone: O33-782 
PE-Cy7 Mouse Anti-human IL-22 eBioscience Cat# 25-7229-42 Clone: 22URTI 
Brilliant Violet 786 Rat Anti-Human and 
ViralIL-10 
BD Biosciences Cat# 564049 Clone: JES3-9D7 
PE Mouse Anti-Human MIP-1β BD Biosciences Cat# 550078 Clone: D21-1351 
APC-H7 Mouse Anti-Human CD45RA BD Biosciences Cat# 560674 Clone: HI100 
Alexa Fluor 647 anti-human CCR7 BioLegend Cat# 353218 Clone: G043H7 
Brilliant Violet 570 anti-human CD3 BioLegend Cat# 300436 Clone: UCHT1 
BUV395 Mouse Anti-Human CD4 BD Biosciences Cat# 563550 Clone: SK3 
Brilliant Violet 711 Mouse Anti-Human CD8 BD Biosciences Cat# 563677 Clone: RPA-T8 
Alexa Fluor 488 anti-human CD45RA BioLegend Cat# 304114 Clone: HI100 
PE-Cy7 anti-human CCR7 BioLegend Cat# 353226 Clone: G043H7 
Brilliant Violet 510 anti-human CD14 BioLegend Cat# 301842 Clone: M5E2 
Brilliant Violet 510 anti-human CD19 BioLegend Cat# 302242 Clone: HIB19 
PE Mouse Anti-Human CD154 BD Biosciences Cat# 555700 Clone: TRAP1 
APC Mouse Anti-Human CD69 BD Biosciences Cat# 340560 Clone: L78 





PBMC samples from HIV-IGRA-,                     
HIV-IGRA+, HIV+IGRA-, HIV+IGRA+ subjects, 
Pulmonary and extrapulmonary TB before       
and after ATT 
St. John’s Medical College 
Hospital, Bangalore, India 
N/A 
PBMC samples from HIV+IGRA+, 
HIV+IGRA+LTNP individuals 
National AIDS Research 
Institute, Pune, India 
N/A 
Chemicals, Peptides, and Recombinant Proteins 
Histopaque 1077 Sigma Aldrich Cat# 10771 
Live/Dead Fixable Aqua Dead Cell Stain Kit Invitrogen  Cat# L34966 
ULtraComp eBeads Invitrogen Cat# 01-2222-42 
   
Remel Phytohemagglutinin Purified ThermoFisher Scientific Cat# R30852801 
SuperScript III Reverse Transcriptase ThermoFisher Scientific Cat# 18080093 
ESAT6/CFP10 fusion protein Department of Infectious 
Diseases, Leiden University 
Medical Center 
N/A 
Latency antigens (Rv1733c, RV1737c, 
Rv2029, RV2628) 
Department of Infectious 
Diseases, Leiden University 
Medical Center 
N/A 
BD FastImmune CD28/CD49d Purified BD Biosciences Cat# 347690, Clone: L293/L25 
Brefeldin A Solution (1,000X) BioLegend Cat# 420601 
Monensin Solution (1,000X) BioLegend Cat# 420701 
BD FACS Lysing Solution 10X Concentrate BD Biosciences Cat# 349202 
BD Phosflow™ Perm/Wash Buffer I BD Biosciences Cat# 557885 
Paraformaldehyde Electron Microscopy 
Sciences 
Cat# 15712-S 
PepMix™ HCMVA (pp65) JPT Peptide Technologies Cat# PM-PP65-2 
HIV-1 PTE Gag Peptide Pool 1 NIH AIDS Reagent Program Cat# 12437 




Critical Commercial Assays 
TruCOUNT kit BD Biosciences Cat# 662415 
Abbott RealTime HIV-1 Viral Load Assay Abbott Molecular Inc. Cat# 06L18-070 
GAPDH Taq Man Gene Expression Assay 
(Hs99999905_m1) 
ThermoFisher Scientific Cat# 4351370 
Taqman gene expression assay    IFN-γ 
(Hs00989291_m1) 
ThermoFisher Scientific Cat# 4331182 
Taqman gene expression assay    IL-2 
(Hs00174114_m1) 
ThermoFisher Scientific Cat# 4331182 
Taqman gene expression assay    MIP-1β 
(Hs99999148_m1) 
ThermoFisher Scientific Cat# 4331182 
HIV GAG Custom TaqMan Probe Assay     
ID: AIHSQJI 
ThermoFisher Scientific Cat# 4331348 
HIV-1 LTR Vanderg Custom TaqMan® Gene 
Expression Assay               ID: APRWEWY 
ThermoFisher Scientific Cat# 4332078 
HUM-CD3-Vanderg Custom TaqMan® Gene 
Expression Assay       ID: APDJXRR 
ThermoFisher Scientific Cat# 4332078 
Single Cell-to-CT™ qRT-PCR Kit ThermoFisher Scientific Cat# 4458236 & 4458237 
Arcturus® PicoPure® DNA Extraction Kit ThermoFisher Scientific Cat# KIT0103 
TaqMan Gene expression Master Mix Applied Biosystems Cat# 4369016 
Amplitaq Gold 360 DNA Polymerase Applied Biosystems Cat# 4398823 
Experimental Models: Cell Lines 
ACH-2 cells Gift from Dr. Udaykumar 
Ranga, JNCASR, Bangalore.  
Sreenath et al., 2010 
HIV (pNL4-3 virus) infected Jurkat T-cells Gift from Dr. Udaykumar 
Ranga, JNCASR, Bangalore. 
Sreenath et al., 2010 
Software and Algorithms 




FlowJo version 9.9.6 Becton, Dickinson & 
Company 
https://www.flowjo.com/ 
FACS DIVA BD Bioscience http://www.bdbiosciences.com/ 
COMPASS Lin L et al.  Nat Biotechnol. 
2015; 33(6):610–616 
www.bioconductor.org › bioc › 
COMPASS › inst › doc 
Pestle v1.8 Roederer M et al. Cytometry 
A. 2011;79(2):167–174. 
https://niaid.github.io/spice/ 
SPICE v5.1 Roederer M et al. Cytometry 
A. 2011;79(2):167–174. 
https://niaid.github.io/spice/ 
7000 System SDS Software v1.2.3 Applied Biosystems https://resource.thermofisher.com/
pages 2013/WE111944/ 
 444 
RESOURCE AVAILABILITY 445 
Lead Contact and Materials Availability 446 
Further information and requests for resources and reagents should be directed to and will be fulfilled by 447 
the Lead Contact, Annapurna Vyakarnam (anna.vyakarnam@kcl.ac.uk). This study did not generate new 448 
unique reagents. 449 
 450 
EXPERIMENTAL MODEL AND SUBJECT DETAILS 451 
Study population 452 
This study was performed in accordance with the relevant guidelines and regulations stated in the 453 
‘Declaration of Helsinki’ and approved by the ethical review Committee of St. John’s Medical College 454 
Hospital, Bangalore, India (Ref no: 55/2015) and the institutional ethics review board of National AIDS 455 
Research Institute (NARI/EC Protocol No.: 2012–06). A total of 205 individuals were recruited at St. 456 
John’s Medical College Hospital, Bangalore, India and 78 at National AIDS Research Institute, Bhosari, 457 
Pune, Maharashtra, India between April 2015 and June 2017. After proper counselling, all participants 458 
provided written informed consent before enrolment. Relevant clinical information was documented in 459 
a proforma and 40 ml blood was drawn from each enrolled individual by venepuncture in ACD, EDTA or 460 




characteristics of the eight clinical groups are listed in Table 1. Detailed information of each participant 462 
has been included in Supplemental File 1. 463 
 464 
HIV uninfected healthy IGRA+ and IGRA- subjects  465 
Healthcare workers of St. John’s National Academy of Health Sciences were recruited through internal 466 
calls highlighting the nature and importance of the study. A commonly used interferon γ (IFN-γ) release 467 
assay (IGRA) for detecting Mycobacterium tuberculosis (Mtb) infection is the QuantiFERON-TB Gold 468 
In-tube test (QFT, Qiagen, Germany) (Auguste et al., 2017). It involves culturing blood cells with Mtb-469 
specific antigens ESAT6, CFP10 and TB7.7 that do not cross react with antigens present in BCG 470 
vaccine or other non-tuberculous mycobacteria. A positive result is considered predictive of infection 471 
with Mtb. The kit also includes a positive control for T-cell activation and IFN-γ release (PHA) and a 472 
negative control (no antigen control) to adjust for spontaneous IFN-γ release. Study participants were 473 
screened based on this IGRA test and were stratified as IGRA+ if their IFN-γ levels were greater than 474 
0.35 IU/ml and IGRA- if the levels were below this cut-off. The detailed IGRA results have been 475 
summarized in the Supplemental Clinical File. All IGRA+ subjects were asymptomatic for TB and had 476 
not received preventive/curative therapy for TB in the past. A total of 88 subjects were recruited and 477 
screened by the IGRA test, of which 26 were IGRA+. Out of 26, 10 IGRA+ subjects were included for the 478 
study; of which 80% were males with a median age of 30 years (25-38). Of the remaining 66, 10 IGRA- 479 
subjects served as uninfected healthy controls, of which 40% were males with a median age of 28 years 480 
(20-39). Healthcare workers in India do not undergo routine IGRA screening at the time of employment. 481 
Hence, ascertaining the duration for which our study subjects were IGRA+ was not possible.  482 
Pulmonary and Extrapulmonary TB 483 
Subjects for this prospective study were enrolled at the Revised National Tuberculosis Program 484 
(RNTCP) clinic of St. John’s Medical College and Hospital. According to the RNTCP guidelines, smear 485 
positivity is considered to be sufficient for diagnosis of pulmonary TB, chest radiograph and sputum 486 
culture is not necessary for TB diagnosis in India. Hence, diagnosis of pulmonary TB was ascertained 487 
by sputum smear microscopy and culture. Standard smear grading of 1+, 2+ and 3+ was used to ascertain 488 




the treating clinician from plain chest radiographs as per the RNTCP standards. GeneXpert MTB/RIF 490 
assay (Cephid, USA), a nucleic-acid amplification (NAA) test of tissue sample approved by RNTCP, was 491 
used for confirmation of diagnosis. All patients included in the study were smear positive and positive 492 
for TB by GeneXpert. Rifampicin resistance by GeneXpert was an exclusion criterion. Sputum samples 493 
were collected for reconfirmation of TB diagnosis by GeneXpert MTB/RIF assay. Consenting adult 494 
patients meeting the above inclusion and exclusion criteria were included. A total of 5 cases of pulmonary 495 
TB were included in the study of which 80% were males with a median age of 34 years (30-66). A diagnosis 496 
of extrapulmonary TB was established from tissue specimens by Ziehl-Neelsen (ZN) staining for 497 
detection of AFB in tissue samples (obtained as surgical specimens/biopsies/FNACs). The site of 498 
extrapulmonary TB varied: 13 cases had cervical lymphadenitis and 2 had tubercular pleural effusions 499 
while the remaining four cases included one each of peritoneal TB, endometrial TB, intestinal TB and 500 
cold abscess. A total of 3 cases of extrapulmonary TB were included in the study of which 66.7% were 501 
males with a median age of 25 years (17-45). Study subjects were treatment naive at the time of 502 
enrolment and were counselled and initiated on standard anti-TB treatment (ATT) based on the directly 503 
observed treatment, short course (DOTS) regimen. Samples from 8 longitudinal donors (PTB, N=5 and 504 
EPTB, N=3) having undergone ATT for a period of 6 to 9 months were used in the study (Table 1). At 505 
a follow up visit 6-9 months from the start of ATT, blood was collected in EDTA or ACD tubes for isolation 506 
of PBMC.  507 
HIV+progressors, LTNP and HIV-TB coinfected patients 508 
Subjects for this prospective study were enrolled at the ICMR-National AIDS Research Institute, Pune. 509 
HIV sero-positivity was confirmed by the standard HIV I and II ELISA test and western blot. CD4+ T-cell 510 
counts were estimated by flow cytometry (FACSCalibur, Becton Dickinson, USA) as a part of routine 511 
investigations using TruCOUNT kit (Becton Dickinson, USA) at baseline and following therapy. HIV-1 RNA 512 
viral loads (copy number/ml) were evaluated in the stored plasma samples using the Abbott Real Time HIV-513 
1 viral load assay (Abbott Molecular Inc., Des Plaines, IL, USA) on the m2000 System (Roche diagnostics, 514 
Germany) at all study visits according to the manufacturer’s instructions. HIV positive subjects attending 515 
the antiretroviral clinic, voluntary counseling and testing center of St John’s Hospital and Medical 516 
College, Bangalore and National AIDS Research Institute, Pune were recruited prospectively into this 517 




exposure prophylaxis were included. Patients having a CD4 count below 350 cells/mm3 were initiated 519 
on anti-retroviral treatment. A thorough physical examination was carried out to rule out opportunistic 520 
infections and concomitant tuberculosis. Whole blood was collected in EDTA vacutainer tubes from each 521 
patient before ART administration for measuring HIV-1 viral load and drug resistance genotyping. Patients 522 
were followed up every 6 months with repeat blood draws for samples from treatment naïve, confirmed 523 
HIV+ subjects, negative for opportunistic infection and TB have been archived for this study with varying 524 
CD4 counts and virus loads. Progressors were defined as antiretroviral treatment (ART)-naïve HIV-525 
infected patients with a CD4 count below 400 cells/mm3 and were also simultaneously tested for TB 526 
specific secretary IFN-γ release by IGRA (Interferon Gamma Release Assay). A total of 10 HIV+IGRA+ 527 
subjects were enrolled in the study of which 50% were males with a median age of 37.5 years (27-56). A 528 
total of 10 HIV+IGRA- subjects were enrolled in the study of which 70% were males with a median age of 529 
31 years (24-47). Long term non progressors (LTNP) were defined as individuals with asymptomatic HIV 530 
infection for 7 or more years who stably maintained their CD4 count above 500 cells/mm3 in absence of 531 
ART (Kulkarni et al., 2017). The mean seropositivity in LTNP cohort was 10.8 years with a range from 7 532 
to 19 years. The CD4 counts of LTNPs at the study visit (median 823 cells/μl [IQR 679–1259]) were 533 
significantly higher than HIV+ progressors (median 352 cells/μl [IQR 289–540]). As expected, the plasma 534 
viral load values at the study visits were significantly lower in LTNPs (median 9943 HIV RNA copies/ml 535 
[IQR 0–19897]) when compared to the values from progressors (median 27926 [IQR 3510–516564]) (Table 536 
1). LTNP subjects selected were also confirmed to be IGRA+. A total of 7 LTNP subjects were enrolled in 537 
the study of which 42.8% were males with a median age of 36.5 years (33-48). The above cohorts were 538 
maintained at National AIDS Research Institute. HIV-TB coinfected patients were recruited at the RNTCP 539 
clinic of St. John’s Medical College and Hospital, of which 8 were used for the study and 87.5% were 540 
males with a median age of 37 years (23-67).  541 
 542 
Sample collection and processing 543 
Peripheral blood mononuclear cells (PBMC) isolated from blood samples within 3 hr of blood draw by 544 
Histopaque (Sigma) density gradient centrifugation were cryopreserved in freezing medium containing 545 





Method Details 548 
Intracellular cytokine staining (ICS) assay and multiparameter flow cytometry 549 
ICS assay with antigen-stimulated PBMCs was performed as previously described (Rakshit et al., 550 
2017). Briefly, cryopreserved PBMCs were thawed and seeded in 96-well round-bottom plates (Costar) 551 
at a concentration of 1 × 106 cells/well after 2hr of rest. Next, 1 µg/ml FastImmune CD28/CD49d (BD 552 
Biosciences) was added that enhances the cytokine production in CD4+ T-cells in response to protein 553 
antigens and peptides by amplifying the signal for T-cell recognition (Kagina et al., 2015). Cells were either 554 
left unstimulated or stimulated overnight with antigens; 10 µg/ml of a pool of 4 DosR regulon-encoded 555 
LT Ag (Rv1733c, Rv1737c, Rv2029 and Rv2628) or secretory Mtb antigen ESAT6/CFP10 (EC) 556 
produced by Kees LMC Franken as recombinant proteins at the Department of Infectious Diseases, 557 
Leiden University Medical Center (Franken et al., 2000),1.7 µg/ml CMVpp65 peptide pool (JPT Peptide 558 
Technologies) and 1 µg/ml Phytohemagglutinin (PHA, Remel), followed by addition of brefeldin A and 559 
monensin (1X, BioLegend) for the last 16 hr. Next day, PBMCs were first stained with Live/Dead fixable 560 
Aqua dead cell stain or AviD (Invitrogen) to exclude dead cells from analysis, for 10 min at room 561 
temperature (RT). Details for all specific and titrated fluorochrome conjugated monoclonal antibodies to 562 
cell surface and intracellular markers used in the intracellular cytokine staining (ICS) assay are listed in 563 
the resource table. For analysis of T-cell responses, cells were stained with cell surface antibodies to 564 
CD45RA-APC-H7 (HI100) and CCR7-Alexa Fluor 647 (G043H7). Cells were then fixed with 1X FACS 565 
lysis buffer (BD Biosciences) for 10 min and permeabilized with 1X BD Perm/Wash buffer (BD 566 
Biosciences) for 20 min. For staining of intracellular cytokines, cells were incubated with a cocktail 567 
containing antibodies to CD3-BV570 (UCHT1), CD4-BUV395 (SK3), CD8-BV711 (RPA-T8), IFN-γ-V450 568 
(B27), TNF-α-FITC (MAb11), IL-2-Alexa Fluor 700 (MQ1-17H12), IL-17A-BV605 (BL168), IL-17F-BV650 569 
(O33-782), IL-10-BV786 (JES3-9D7), IL-22-PE-Cy7 (22URTI) and MIP-1β-PE (D21-1351). Antibody 570 
incubations were all performed at RT for 30 min in the dark. Cells were washed, fixed in 1% 571 
paraformaldehyde and kept at 4°C until acquisition. 572 




Samples were analyzed by flow cytometry using on BD FACSAriaTM Fusion flow cytometer (BD 574 
Biosciences, San Jose, CA) and the associated BD FACSDivaTM version 8.0.1 software Cytometer 575 
Setting and Tracking (CST) beads (BD Biosciences) were acquired before each experiment to ensure 576 
that cytometer parameters remained consistent across all experiments. Stained samples were acquired 577 
with a standard stopping gate set at 200,000 CD3 lymphocytes. Negative and single-stained 578 
compensation beads (eBioscience) were acquired for each experiment, before sample acquisition, and 579 
used to calculate the compensation matrix. Data was then analyzed using the FlowJo version 9.9.6 580 
software (FlowJo), Pestle v1.8, SPICE v5.1 (Roederer et al., 2011) as described previously. Briefly, 581 
CD4+ T-cells expressing all possible combinations (256 subsets) of 8 effector cytokines were analyzed 582 
by Boolean gating in FlowJo. After careful analysis, the data was further analyzed by SPICE which 583 
identified 6 unique Th17 subsets that either expressed IFN-γ or IL-10 in combination with IL-17A/IL-584 
17F/IL-22. These subsets were positive only for these cytokines and with no expression of other 585 
cytokines (IL-2, TNF-α and MIP-1β). 586 
COMPASS analysis of flow cytometry data 587 
Cell counts were analyzed using the COMPASS algorithm as described. Briefly, COMPASS is a statistical 588 
model developed for high-dimensional flow cytometry data analysis that can detect antigen-specific 589 
changes across all observable functional T-cell subsets, without the need to limit the analysis to very 590 
specific subsets based on expected biological significance (Lin et al., 2015). In COMPASS, responses are 591 
quantified using posterior probabilities that summarize for each subject and subset the evidence that the 592 
corresponding response is Ag specific by comparing the proportion of cytokine-positive cells in the Ag 593 
sample to the corresponding proportion in the control sample. Polyfunctionality scores were calculated from 594 
posterior responses probabilities, summarizing a subject’s entire T-cell functionality profile into a single 595 
number. In this study, we have applied COMPASS to each of the antigens in CD4+ T-cell subsets leading 596 
to 20 analyses. Each one of the analyses was unbiased and considered all of the 256 possible cytokine 597 
functions (defined as Boolean combination). In order to evaluate differences in polyfunctionality between 598 
groups, a linear model estimating the group wise mean polyfunctionality scores was fit to each antigen and 599 
the difference between IGRA+ and other groups was tested (Wald test, null:, two-sided test). Resulting p-600 
values were adjusted for multiple testing (across all 60 tests and models) to control the FDR (false discovery 601 




called at the 5% FDR level. Magnitudes of T-cell responses were calculated independent of COMPASS as 603 
the maximum of zero or the proportion of gated events in the stimulated condition minus the proportion of 604 
gated events in the unstimulated condition. 605 
 606 
Capture of antigen-specific CD4+ T-cells 607 
Cryopreserved PBMCs were thawed, rested for 2 hr and plated in U bottom 96 well plate at 1 × 106/ well., 608 
Cells were then blocked with 0.5 µg/ml CD40 (HB14) antibody for 15 min at 37°C. Blocking antibody to 609 
CD40 prevents CD154 downregulation and thereby facilitates capture of CD154+ antigen specific CD4+ T-610 
cells (Frentsch et al., 2005). Next, anti-CD28/CD49d costimulatory antibody and antigens (CMVpp65, EC, 611 
LT Ag and HIV-PTE (Env-1-3, and Gag 1-2) pools were added for 16 hr. Next day, PBMCs were stained 612 
with AviD the monoclonal antibodies to CD3-BV570 (UCHT1), CD4-BUV395 (SK3), CD8-BV711 (RPA-613 
T8), CD45RA-Alexa Fluor 488 (HI100), CCR7-PE-Cy7 (G043H7), CD14-BV510 (M5E2), CD19-BV510 614 
(HIB19), CD154-PE (TRAP1), CD69-APC (L78) listed in resource table and sorted on a BD FACSAria 615 
Fusion flow cytometer with a 100 µm nozzle, 15 psi, 100 rpm agitation at 4°C with a flow rate of 3000–6000 616 
events/sec. Cells were sorted using FACS Diva software to isolate antigen-specific 617 
(CD3+CD4+CD154+CD69+) and resting (CD3+CD4+CD154-CD69-) CD4+ T-cells, referred to as 618 
CD154+CD69+ and CD154-CD69- henceforth, for quantification of cell-associated HIV DNA and HIV RNA . 619 
 DNA isolation 620 
DNA isolation was performed using Arcturus Pico Pure DNA kit (ThermoFisher Scientific) as per 621 
manufacturer’s instructions. Isolated DNA was directly used in the pre-amplification PCR performed in the 622 
same tube for both HIV-1 LTR and human CD3 gene.  623 
Real Time quantitative PCR (qPCR) for quantification of total cell-associated HIV DNA  624 
Total cell associated HIV DNA was quantified by the method described previously (Vandergeeten et al., 625 
2014) with some modifications. qPCR was performed using custom synthesized HIV-1 LTR and human 626 
CD3 gene based TaqMan Gene expression assays and TaqMan Gene expression Master Mix (Applied 627 




the manufacturer's recommendations. Before qPCR, DNA prepared from sorted cells was subjected to pre-629 
amplification PCR performed in single tube of 50 l PCR reaction volume for both HIV-1 LTR and human 630 
CD3 gene using Amplitaq Gold 360 DNA Polymerase. The absolute quantity of cell associated HIV DNA 631 
was calculated based on standard curves of ACH-2 cells, which carry a single copy of the integrated HIV 632 
genome, which were used to generate standard curves for both HIV-1 LTR and human CD3 gene (Figure 633 
S10). Series of ten-fold dilutions of ACH-2 cells DNA corresponding to 3 × 105 to 3 HIV-1 DNA copies per 634 
reaction was included in each experiment in order to generate standard curves for both HIV-1 LTR as well 635 
as human CD3 gene. Individual standard curves from each experiment were used to determine the copy 636 
number of HIV-1 LTR and human CD3 gene respectively. All samples were analyzed in duplicate. The 637 
result of the cell associated HIV-1 DNA quantification was expressed as number of HIV DNA copies per 638 
million CD4+ T-cells. Two negative controls are typically included in each plate: DNase/RNase-free water, 639 
as a control for the PCR (no template control, NTC) and DNA extracted from the HIV uninfected Jurkat T-640 
cells. Additionally, DNA extracted from sorted CD4+ T-cells from PBMCs of HIV sero-negative healthy 641 
individuals were also included in few experiments to demonstrate the specificity of HIV-1 LTR qPCR assay. 642 
DNA extracted from the HIV (pNL4-3 virus) infected Jurkat T-cells was also included as positive control in 643 
each assay. Human CD3 gene was quantified in order to determine the input level of cellular DNA in the 644 
sample and was used as an endogenous reference to normalize variations due to differences in the cell 645 
count or DNA extraction. Total HIV DNA copies per million cells were determined by calculating the number 646 
of cells from the human CD3 gene copy number which is present as 2 copies of CD3 gene per cell.  647 
 648 
Linearity, specificity and sensitivity of qPCR assay to quantify cell-associated HIV DNA  649 
The dynamic range of the assay for both HIV-1 LTR and Human CD3 gene encompassed at least 6 orders 650 
of magnitude, with a strong linear relationship (r2 >0.998) between the Ct values and log10 input number 651 
of gene copies. HIV-1 LTR signal was never detected in any of the experiments in the negative control DNA 652 
(DNA of HIV negative Jurkat T-cells and sorted CD4 T-cells from PBMCs of HIV sero-negative healthy 653 
person) indicating the specificity of the qPCR assay for HIV-1 LTR. For DNA from HIV negative Jurkat T-654 
cells the median Ct value for human CD3 gene from 10 experiments was 22.36 (Range: 19.95 – 23.52) 655 
and no HIV-1 LTR signal was detected in any of the 10 experiments. When DNA of sorted CD4 T-cells from 656 
PBMCs from HIV sero-negative healthy donor were tested in two experiments, the mean Ct for human CD3 657 




HIV-1 LTR qPCR assays were highly sensitive and could detect as low as single copy of the target gene in 659 
the 20 l of template DNA used in the pre-amplification PCR reaction. 660 
 661 
Relative quantification of cytokines and cell-associated HIV-1 RNA  662 
Single Cell-to-CT kit was used to quantify cell-associated HIV-1 RNA. For each stimulation 100 to 250 cells 663 
(CD154+CD69+ or CD154-CD69-) were directly sorted into 10µl single cell lysis solution containing 1µl of 664 
single cell DNase I. Single Cell Stop solution (1µl) was added to stop the lysis reaction, followed by a 2min 665 
incubation at RT prior to freezing at -20°C. cDNA synthesis and pre-amplification were done according to 666 
manufacturer's instructions. TaqMan Probes used for pre-amplification (and later used for qPCR) were: 667 
GAPDH (reference gene, Hs99999905_m1), GAG mRNA (in-house custom designed), IFN-γ 668 
(Hs00989291_m1), IL-2 (Hs00174114_m1) and MIP-1β (Hs99999148_m1). After pre-amplification, the 669 
samples were stored at -20°C. For gene expression analysis of the cDNA, a downscaled version of the 670 
qPCR protocol supplied with the Single Cell-to-CT kit was used, with reactions performed in 10µl, 671 
comprising of 5µl 2X TaqMan Gene Expression Master Mix supplied with the kit, 5 times diluted cDNA 672 
sample, 0.5µl of 20X TaqMan probes and nuclease-free water. All qPCR reactions were performed in a 96-673 
well plate (Eppendorf), in duplicate and Cq values were averaged. Relative copy number (RCNgene) was 674 
calculated against CT values of GAPDH mRNA levels in each sample (equation 1). All the gene expressions 675 
(GAG, IFN-γ, IL-2 and MIP-1β are represented as Fold Change (FCgene, equation 2) by dividing RCNgene by 676 
the median RCN of the same genes from unstimulated cells (RCNmed.unstimulated). Data is represented 677 
irrespective of the sorted CD4+ cell type. 678 
RCNgene = power (2, -(∆CTgene – ∆CTGAPDH)) (1) 679 
FCgene = RCNgene / RCNmed.unstimulated (2) 680 
Clinical subjects with GAPDH CT in the range of 15 to 27 were considered. In order to confirm that the CT 681 
values for GAG-gene were indeed equivalent to actual gene expression and not any non-specific signal, 682 
control experiments were carried out using uninfected PBMCs and 250 cells were sorted for unstimulated 683 
and antigen-stimulated cells. qPCR was carried out on these samples for the above mentioned TaqMan 684 
probes. The GAG gene RCN of uninfected PBMCs were considered to be non-specific binding (background 685 
noise) of TaqMan probe and clinical subjects with GAG gene CT to be greater than 32 were removed and 686 





Statistical Analysis 689 
All antigen-stimulated wells were adjusted for non-specific responses by background subtraction (media 690 
alone). Statistical analyses were performed and graphs were created using GraphPad Prism software 691 
version 6.0.7 (GraphPad, La Jolla, CA). Paired longitudinal comparisons within the same group were done 692 
using the Wilcoxon matched-pairs signed rank test. Comparisons across two treatment groups were done 693 
using unpaired Mann–Whitney test. The p values were reported unadjusted, but were interpreted after 694 
adjustment using the Bonferroni correction for multiple comparisons. Statistical analyses across seven 695 
clinical groups was performed using a one-way ANOVA nonparametric Kruskal–Wallis test and corrected 696 
by Dunn’s test for multiple comparisons.  697 
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FIGURE LEGENDS 868 
Figure 1: HIV infection impairs the expression of effector cytokines in Mtb-specific CD4+ T-cells. 869 
PBMCs from (A) HIV-IGRA+ (N=10, green) vs. HIV+IGRA+ (N=10, red) and (B) HIV-IGRA- (N=10, brown) vs. 870 
HIV+IGRA- (N=10, blue) subjects were stimulated overnight with EC (10µg/ml), LT Ag (10µg/ml), CMVpp65 871 
(1.7µg/ml) and PHA (1µg/ml). All HIV+ subjects were initiated on ART after collection of blood at baseline 872 
post diagnosis. CD3+CD4+ T-cells were analyzed for intracellular expression of IFN-γ, IL-2, MIP-1β, TNF-873 
α, IL-10 and IL-17F in a standard ICS assay. Frequencies of cytokine-producing total CD4+ T-cells were 874 
obtained after background subtraction of values from unstimulated control. Absolute numbers of antigen-875 
specific CD4+ T-cells were calculated by multiplying the frequencies of cytokine-positive CD4+ T-cells by 876 
the total CD4 T-cell count. Box-and-whisker plots show the inter-quartile range and horizontal bars 877 
represent the median absolute numbers of total cytokine-positive CD4+ T-cells. Statistical analysis was 878 
performed by Mann-Whitney two-tailed t test: with Bonferroni’s correction for multiple comparisons. 879 
 880 
Figure 2: COMPASS and SPICE analysis reveals HIV infection reduces CD4+ polyfunctional 881 
responses to EC and LT Ag in IGRA+ and IGRA- subjects. PBMCs were stimulated overnight with EC 882 
and LT Ag and CD3+CD4+ T-cells were analyzed for intracellular expression of IFN-γ, IL-2, MIP-1β, TNF-883 
α, IL-10 and IL-17F in a standard ICS assay. All HIV+ subjects were initiated on ART after collection of 884 
blood at baseline post diagnosis. Boolean gates were created from the individual cytokine (listed above) in 885 
FlowJo to divide responding cells into 64 distinct subsets corresponding to all possible combinations of 886 
these functions and the data was analyzed using COMPASS and SPICE software. (A) Box plots show Mtb-887 
specific CD4+ T-cell polyfunctionality scores (PFS) analyzed by COMPASS in HIV-IGRA+ (green), 888 
HIV+IGRA+ (red), and HIV+IGRA- (blue). For each antigen, pairwise differences between HIV-IGRA+ and 889 
other groups were based on a group wise linear model fit to the PFS (null: βgroup−βHIV-IGRA+=0 two-sided test) 890 
and p-values adjusted for multiple testing (see methods). (B) SPICE analyses for in-depth phenotypic 891 
profiling of Mtb-specific CD4+ T-cells in HIV-IGRA+ (N=10), HIV+IGRA- (N=10), and HIV+IGRA+ (N=10) 892 
subjects. Each slice of the pie corresponds to a distinct combination of 6 cytokines (IFN-γ, IL-2, TNF-α, IL-893 
17F, IL-10 and MIP-1β) produced in response to EC and LT Ag stimulation. The pie charts depict the mean 894 
frequency for each of the 64 possible phenotypic profiles of Mtb-specific CD4+ T-cells. The arcs surrounding 895 
the pie charts indicate the proportion of the responses contributed by each of the single cytokines. A key to 896 





Figure 3: HIV infection leads to skewing of Th17 response in HIV+IGRA+ chronic progressors but 899 
not in long-term non-progressors. PBMCs were cultured overnight in the presence or absence of EC 900 
and LT Ag. CD3+CD4+ T-cells were analyzed for intracellular expression of IFN-γ, IL-17A, IL-17F, IL-22 and 901 
IL-10. Boolean gates were created from the individual cytokine (listed above) in FlowJo to divide responding 902 
cells into 256 distinct subsets corresponding to all possible combinations of these functions and the data 903 
was analyzed using COMPASS and SPICE software. All HIV+ subjects were initiated on ART after collection 904 
of blood at baseline post diagnosis. (A) Boxplots of data analyzed in COMPASS is shown for the HIV-IGRA+ 905 
(N=10, green), HIV+IGRA+ (N=10, red) and HIV+IGRA- (N=10, blue) groups of probability scores of antigen-906 
specific response for each subject, averaged across selected functional profiles (either IFN-γ+ or IL-10+ cells 907 
together with all combinations of IL-17A, IL-17F and IL-22) and across EC or for LT Ag. Probabilities are 908 
derived from a COMPASS model fit to ICS data using the Th17 panel. A p-value is shown tested for a 909 
difference between groups (two-sided t-test). (B) HIV-IGRA+ (N=10, green) and HIV+IGRA+ (N=10, red) 910 
subjects were chosen for comparison of the individual Th17 proinflammatory (IFN-γ+IL-17A+, IFN-γ+IL-17F+, 911 
IFN-γ+IL-22+) or regulatory (IL-10+IL-17A+, IL-10+IL-17F+, IL-10+IL-22+) subsets and in (C) HIV-IGRA- (N=10, 912 
brown), HIV-IGRA+ (N=10, green), HIV+IGRA- (N=10, blue), HIV+IGRA+ (N=10, red), HIV+IGRA+LTNP (N=7, 913 
magenta), HIV-TB+ (N=10, black) and HIV+TB+ (N=8, dark grey) subjects were compared for combined 914 
double positive Th17 proinflammatory (IFN-γ with IL-17A/IL-17F/IL-22) or regulatory (IL-10 with IL-17A/IL-915 
17F/IL-22) subsets and Tr1 cells (IFN-γ+IL10+) in response to EC or LT Ag pool stimulation. Box-and-916 
whisker plots analyzed by SPICE show the inter-quartile range in absolute numbers with horizontal bar 917 
representing the median of (B) individual or (C) combined cellular subsets. Statistical analysis was 918 
performed using a one-way ANOVA nonparametric Kruskal–Wallis test and corrected by Dunn’s test for 919 
multiple comparisons. 920 
 921 
Figure 4: ART and ATT modulate CD4+ T effector cytokine responses in HIV+ and TB+ patients. (A) 922 
PBMCs from HIV+IGRA- and HIV+IGRA+ (N=9) patients before (-ART in red) and after treatment (+ART in 923 
blue) were stimulated overnight with EC and LT Ag. (B) PBMCs from HIV-TB+ (N=8) patients before (-ATT 924 
in red) and after treatment (+ATT in blue) were stimulated overnight with EC and LT Ag. In both (A) and (B), 925 
CD3+CD4+ T-cells were analyzed for intracellular expression of IFN-γ, IL-2, MIP-1β, TNF-α, IL-10 and IL-926 




treatment (+ART or +ATT) with treatment naive controls (-ART or -ATT). Horizontal capped lines represent 928 
statistical comparisons between matched patients. Statistical analysis was performed by Wilcoxon 929 
matched-pairs signed-rank test with post-hoc Bonferroni’s correction for multiple comparisons. 930 
 931 
Figure 5: ART and ATT restore regulatory Th17 response in HIV-infected and active TB patients. (A) 932 
PBMCs from HIV+ subjects (N=9) before (-ART, red) and after 1 year of treatment (+ART, blue) were 933 
cultured overnight in the presence or absence of EC and LT Ag. (B)  PBMCs from HIV-TB+ patients (N=8) 934 
before (-ATT, red) and after 6 months treatment (+ATT, blue) were cultured overnight in the presence or 935 
absence of EC and LT Ag. In both (A) and (B), CD3+CD4+ T-cells were analyzed for expression of IL-17A, 936 
IL-17F, IL-22 in combination with IFN-γ or IL-10 using SPICE. Dots connected with full lines represent 937 
matched pairs of patients post treatment with treatment naive controls. Horizontal capped lines represent 938 
statistical comparisons between matched patients. Statistical analysis was performed using the Wilcoxon 939 
matched-pairs signed rank test with post-hoc Bonferroni’s correction for multiple comparisons.  940 
 941 
Figure 6: Comparable cytokine production in activated CD3+CD4+CD45RA-CD154+CD69+ cells and 942 
its un-activated CD3+CD4+CD45RA-CD154-CD69- counterpart in HIV-infected subjects irrespective 943 
of antigen-specificity. (A) Schematic overview of flow cytometry-based cell sorting of antigen-specific 944 
memory CD4+ T-cells for quantification of cell associated HIV DNA, HIV RNA and cytokines. PBMCs from 945 
HIV+ IGRA- and IGRA+ subjects (N=20) were stimulated with EC, LT Ag, HIV-PTE (Gag/Env) pool and CMV 946 
for 16 hr. Next, 100 to 250 effector cells were sorted for CD3+CD4+CD45RA-CD154+CD69+ and 947 
CD3+CD4+CD45RA-CD154-CD69- populations in single cells-to-CT lysis buffer for quantification of cytokine 948 
mRNA. Comparison of (B) IFN-γ, (C) IL-2 and (D) MIP-1β gene expression in sorted cells of different 949 
antigen specificities. The cDNA was pre-amplified for cytokine mRNA along with GAPDH (reference gene). 950 
The fold change of cytokine mRNA is shown in CD154+ vs CD154- T-cells which indicates efficient activation 951 
of CD3+CD4+CD45RA-CD154+CD69+ and not its bystander counterpart CD3+CD4+CD45RA-CD154-CD69- 952 
T-cells by various antigens. Statistical analysis was performed using the Wilcoxon matched-pairs signed 953 
rank test.  954 
 955 
Figure 7: Cell-associated HIV DNA and HIV RNA does not significantly vary among cells of different 956 




stimulated with anti-CD28/CD49d costimulatory antibody and antigens [EC, LT Ag, CMVpp65 and HIV-PTE 958 
(Env-1-3, and Gag 1-2)] pools for 16 hr. Cells were sorted (according to the protocol shown in Figure 6A) 959 
to isolate antigen-specific (CD154+CD69+) and resting (CD154-CD69-) memory (CD45RA-) CD4+ T-cells, 960 
for quantification of cell-associated HIV DNA and HIV RNA. For each subject, 100 to 250 cells were directly 961 
sorted into 10µl single cells-to-Ct lysis buffer for RNA extraction whereas remainder cells were collected in 962 
2% RPMI for DNA extraction. (A) HIV DNA copy number was estimated in different Ag-specific -963 
CD154+CD69+ cells. (B) Comparison of HIV DNA copy number in CD154+CD69+ vs. CD154-CD69- cells 964 
stimulated with different antigens. (C) Comparative fold change of HIV GAG mRNA in antigen-stimulated 965 
CD154+CD69+ cells relative to its unstimulated control. (D) Comparison of HIV GAG mRNA CD154+CD69+ 966 
vs. CD154+CD69+ cells upon stimulation with different antigens. Statistical analysis was performed using 967 
the Kruskal-Wallis test and Wilcoxon matched-pairs signed rank test. 968 




TABLE 1: Clinical details of study participants. 970 
 971 
 972 
*M: Male; F: Female 973 
 974 
 975 
# Thakar et al., 2011 976 
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1Year POST ART  
9 M=4; F=5 
 
32 (24-56) 484 (282-524) Not detected or <40 
Pulmonary TB  
BL & 6 MONTHS  
POST ATT 
5 M=4; F=1 
 





Extrapulmonary TB  
BL & 6 MONTHS  
POST ATT 





HIV-TB 8 M=7; F=1 37 (23-67) 1495 (64-259) 194500 (26200-
1160000) 
KEY RESOURCES TABLE 
 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 
V450 Mouse Anti-Human IFN-γ BD Biosciences Cat# 560371 Clone: B27 
FITC Mouse Anti-Human TNF BD Biosciences Cat# 552889 Clone: MAb11 
Alexa Fluor 700 anti-human IL-2 BioLegend Cat# 500320 Clone: MQ1-17H12 
Brilliant Violet 605 anti-human IL-17A BioLegend Cat# 512326 Clone: BL168 
Brilliant Violet 650 Mouse Anti-Human IL-17F BD Biosciences Cat# 564264 Clone: O33-782 
PE-Cy7 Mouse Anti-human IL-22 eBioscience Cat# 25-7229-42 Clone: 22URTI 
Brilliant Violet 786 Rat Anti-Human and 
ViralIL-10 
BD Biosciences Cat# 564049 Clone: JES3-9D7 
PE Mouse Anti-Human MIP-1β BD Biosciences Cat# 550078 Clone: D21-1351 
APC-H7 Mouse Anti-Human CD45RA BD Biosciences Cat# 560674 Clone: HI100 
Alexa Fluor 647 anti-human CCR7 BioLegend Cat# 353218 Clone: G043H7 
Brilliant Violet 570 anti-human CD3 BioLegend Cat# 300436 Clone: UCHT1 
BUV395 Mouse Anti-Human CD4 BD Biosciences Cat# 563550 Clone: SK3 
Brilliant Violet 711 Mouse Anti-Human CD8 BD Biosciences Cat# 563677 Clone: RPA-T8 
Alexa Fluor 488 anti-human CD45RA BioLegend Cat# 304114 Clone: HI100 
PE-Cy7 anti-human CCR7 BioLegend Cat# 353226 Clone: G043H7 
Brilliant Violet 510 anti-human CD14 BioLegend Cat# 301842 Clone: M5E2 
Brilliant Violet 510 anti-human CD19 BioLegend Cat# 302242 Clone: HIB19 
PE Mouse Anti-Human CD154 BD Biosciences Cat# 555700 Clone: TRAP1 
APC Mouse Anti-Human CD69 BD Biosciences Cat# 340560 Clone: L78 
CD40 antibody, Mouse Anti-human Miltenyi Biotec  Cat# 130-094-133 Clone: HB14 
Biological Samples 
PBMC samples from HIV-IGRA-,                     
HIV-IGRA+, HIV+IGRA-, HIV+IGRA+ subjects, 
Pulmonary and extrapulmonary TB before       
and after ATT 
St. John’s Medical College 
Hospital, Bangalore, India 
N/A 
Key Resource Table
PBMC samples from HIV+IGRA+, 
HIV+IGRA+LTNP individuals 
National AIDS Research 
Institute, Pune, India 
N/A 
Chemicals, Peptides, and Recombinant Proteins 
Histopaque 1077 Sigma Aldrich Cat# 10771 
Live/Dead Fixable Aqua Dead Cell Stain Kit Invitrogen  Cat# L34966 
ULtraComp eBeads Invitrogen Cat# 01-2222-42 
   
Remel Phytohemagglutinin Purified ThermoFisher Scientific Cat# R30852801 
SuperScript III Reverse Transcriptase ThermoFisher Scientific Cat# 18080093 
ESAT6/CFP10 fusion protein Department of Infectious 
Diseases, Leiden University 
Medical Center 
N/A 
Latency antigens (Rv1733c, RV1737c, 
Rv2029, RV2628) 
Department of Infectious 
Diseases, Leiden University 
Medical Center 
N/A 
BD FastImmune CD28/CD49d Purified BD Biosciences Cat# 347690, Clone: L293/L25 
Brefeldin A Solution (1,000X) BioLegend Cat# 420601 
Monensin Solution (1,000X) BioLegend Cat# 420701 
BD FACS Lysing Solution 10X Concentrate BD Biosciences Cat# 349202 
BD Phosflow™ Perm/Wash Buffer I BD Biosciences Cat# 557885 
Paraformaldehyde Electron Microscopy 
Sciences 
Cat# 15712-S 
PepMix™ HCMVA (pp65) JPT Peptide Technologies Cat# PM-PP65-2 
HIV-1 PTE Gag Peptide Pool 1 NIH AIDS Reagent Program Cat# 12437 
HIV-1 PTE-G Env Peptide Pool 1 NIH AIDS Reagent Program Cat# 12698 
Critical Commercial Assays 
TruCOUNT kit BD Biosciences Cat# 662415 
Abbott RealTime HIV-1 Viral Load Assay Abbott Molecular Inc. Cat# 06L18-070 
GAPDH Taq Man Gene Expression Assay 
(Hs99999905_m1) 
ThermoFisher Scientific Cat# 4351370 
Taqman gene expression assay    IFN-γ 
(Hs00989291_m1) 
ThermoFisher Scientific Cat# 4331182 
Taqman gene expression assay    IL-2 
(Hs00174114_m1) 
ThermoFisher Scientific Cat# 4331182 
Taqman gene expression assay    MIP-1β 
(Hs99999148_m1) 
ThermoFisher Scientific Cat# 4331182 
HIV GAG Custom TaqMan Probe Assay     
ID: AIHSQJI 
ThermoFisher Scientific Cat# 4331348 
HIV-1 LTR Vanderg Custom TaqMan® Gene 
Expression Assay               ID: APRWEWY 
ThermoFisher Scientific Cat# 4332078 
HUM-CD3-Vanderg Custom TaqMan® Gene 
Expression Assay       ID: APDJXRR 
ThermoFisher Scientific Cat# 4332078 
Single Cell-to-CT™ qRT-PCR Kit ThermoFisher Scientific Cat# 4458236 & 4458237 
Arcturus® PicoPure® DNA Extraction Kit ThermoFisher Scientific Cat# KIT0103 
TaqMan Gene expression Master Mix Applied Biosystems Cat# 4369016 
Amplitaq Gold 360 DNA Polymerase Applied Biosystems Cat# 4398823 
Experimental Models: Cell Lines 
ACH-2 cells Gift from Dr. Udaykumar 
Ranga, JNCASR, Bangalore.  
Sreenath et al., 2010 
HIV (pNL4-3 virus) infected Jurkat T-cells Gift from Dr. Udaykumar 
Ranga, JNCASR, Bangalore. 
Sreenath et al., 2010 
Software and Algorithms 
GraphPad Prism 8.0.2 GraphPad Software https://www.graphpad.com/ 
FlowJo version 9.9.6 Becton, Dickinson & 
Company 
https://www.flowjo.com/ 
FACS DIVA BD Bioscience http://www.bdbiosciences.com/ 
COMPASS Lin L et al.  Nat Biotechnol. 
2015; 33(6):610–616 
www.bioconductor.org › bioc › 
COMPASS › inst › doc 
Pestle v1.8 Roederer M et al. Cytometry 
A. 2011;79(2):167–174. 
https://niaid.github.io/spice/ 
SPICE v5.1 Roederer M et al. Cytometry 
A. 2011;79(2):167–174. 
https://niaid.github.io/spice/ 
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Supplemental Information 
 
Figure S1: Schematic representation of flow cytometry data and sequential gating strategy used 
to detect cytokine production by CD4+ T cells in a HIV+IGRA+ subject upon EC stimulation. Initial 
gating was done on FSC-H and FSC-A to discriminate singlets, followed by the exclusion of dead cells 
by AVID stain. Lymphocytes were gated using FSC-A and SSC-A. Within the lymphocyte gate, CD3+ 
cells were first identified, followed by CD4+ and CD8+ T cells. To define functional markers for CD4+ T 
cells, a gate was applied for each cytokine, not taking into account the co-expression of other markers. 
All gates for non-functional markers were defined using fluorescence minus one (FMO) controls; gates 
for functional markers were defined using the unstimulated samples. CD4+ T cells expressing Th17 
cytokines in combination with IL-10 or IFN-γ are also shown by quadrant gating. Boolean gates were 
then created based on these gates to identify cells expressing different combination of markers. 
 
 





























Figure S2: Expression of effector cytokines by CD4+ T cells in the four clinical groups. PBMCs 
were stimulated overnight with EC (10µg/ml), LT Ag (10µg/ml) and CMVpp65 (1.7µg/ml). CD3+CD4+ T-
cells were analysed for intracellular expression of IFN-γ, IL-2, MIP-1β, TNF-α, IL-10 and IL-17F in a 
standard ICS assay. Representative FACS plots gated on CD4+ T cells showing cytokine expression 
from (A) HIV-IGRA+ vs. HIV+IGRA+ and (B) HIV-IGRA- vs. HIV+IGRA- subjects in absence of stimulation 
(UNS) and in response to EC, LT Ag and CMV stimulation. The values (in blue) within the gates indicate 
the frequencies of cytokine-producing total CD4+ T-cells. 
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Figure S3: HIV infection modulates the expression of effector cytokines in Mtb-specific CD4+ T-
cells. PBMCs from (A) HIV-IGRA+ (N=10, green) vs. HIV+IGRA+ (N=10, red) and (B) HIV-IGRA- (N=10, 
brown) vs. HIV+IGRA- (N=10, blue) subjects were stimulated overnight with ESAT6/CFP10 (10µg/ml), 
LT Ag pool (10µg/ml), CMVpp65 (1.7µg/ml) and PHA (1µg/ml). CD3+CD4+ T-cells were analysed for 
intracellular expression of IFN-γ, IL-2, MIP-1β, TNF-α, IL-10 and IL-17F in a standard ICS assay. 
Frequencies of cytokine-producing total CD4+ T-cells were obtained after background subtraction of 
values from unstimulated control. Box-and-whisker plots show the inter-quartile range and horizontal 
bars represent the median frequencies of total cytokine-positive CD4+ T-cells. Statistical analysis was 




Figure S4: HIV infection does not significantly modulate the expression of effector cytokines in 
Mtb-specific CD8+ T-cells. PBMCs from HIV-IGRA+ (N=10, green) vs. HIV+IGRA+ (N=10, red) and HIV-
IGRA- (N=10, brown) vs. HIV+IGRA- (N=10, blue) subjects were stimulated overnight with 
ESAT6/CFP10 (10µg/ml) and LT Ag pool (10µg/ml). CD3+CD8+ T-cells were analysed for intracellular 
expression of IFN-γ and TNF-α in a standard ICS assay. (A) Frequencies of cytokine-producing total 
CD8+ T-cells were obtained after background subtraction of values from unstimulated control. (B) 
Absolute numbers of antigen-specific CD8+ T cells were calculated by multiplying the frequencies of 
cytokine-positive CD8+ T cells by the total CD8+ T-cell count. Box-and-whisker plots show the inter-
quartile range and horizontal bars represent the median frequencies or absolute numbers of total 
cytokine-positive CD8+ T-cells. Statistical analysis was performed by Mann-Whitney test with 











Figure S5: CMV-specific responses in HIV-uninfected and HIV-infected individuals. PBMCs from 
HIV-IGRA+, HIV+IGRA+, HIV-IGRA- and HIV+IGRA- (N=40) subjects were stimulated overnight with CMV 
(1.7µg/ml). CD3+CD4+ and CD3+CD8+ T-cells were analysed for intracellular expression of IFN-γ and 
TNF-α in a standard ICS assay. Absolute numbers of antigen-specific CD4+ and CD8+ T cells were 
calculated by multiplying the frequencies of cytokine-positive CD4+ and CD8+ T cells by the total CD4+ 
and CD8+ T-cell count respectively. Box-and-whisker plots show the inter-quartile range and horizontal 

















Figure S6: HIV infection dramatically impacts the polyfunctional response. Stacked COMPASS 
heat maps displaying CD4+ T cell responses to EC and LT Ag in three clinical groups. In the heat map, 
columns correspond to the different disjoint cell subsets in which responses were detected and are 
color-coded by the cytokines they express (white = “off”, shaded = “on”, grouped by colour = “degree of 
functionality”), and are displayed in order of increasing functionality from left to right i.e. sky blue 
representing one cytokine to peach representing combinations of 5 cytokines. For example, the first 
column represents CD4+ T cells that produce MIP-1β but none of the other functions. Rows represent 
study subjects (N = 10 per group), which are ordered by their infection status: HIV-IGRA+ (top, green), 
HIV+IGRA- (middle, pink) and HIV+IGRA+ (bottom, blue), and by PFS within each group. Each cell of 
the heatmap shows the probability estimated by COMPASS that the observed response is antigen-
specific in the corresponding subject (row) and cell subset (column), where the probability is color-
coded from white (zero) to purple (one). A probability of 0 indicates certainty that the observed response 
is background, while a probability of 1 indicates certainty that the observed response is antigen-specific. 
 
 
Figure S7: Gating strategy for Th17 subsets in HIV uninfected and infected IGRA+ and IGRA- 
subjects. Representative FACS plots gated on CD4+ T cells showing the proinflammatory IFN-γ+Th17 
(IFN-γ with IL-17A/IL-17F/IL-22) and regulatory IL-10+ Th17 (IL-10 with IL-17A/IL-17F/IL-22) subsets in 




Figure S8: Backgating to show IL-10+ Th17 and IFN-γ+ Th17 cells that represent minor but viable 















Figure S9: Comparison of CD4 T cell count (cells/mm3) vs. viral load (copies/ml) in HIV infected 






















Figure S10: Human CD3 and HIV-1 LTR standard curves for quantification of cell-associated HIV 
DNA in sorted Ag-specific CD4 T cells of HIV-infected subjects. Standard curves were generated 
using 10-fold serial dilution series of ACH-2 cellular DNA for both HIV-1 LTR and Human CD3 gene in 
each of the 11 different experiments. LTR and CD3 copy numbers were calculated from the respective 
standard curves of each individual experiment and total cell associated HIV DNA copies per million 
CD4+ T-cells were determined by calculating the number of cells from the human CD3 gene copy 
number which is present as 2 copies of CD3 gene per cell. Mean standard curves for human CD3 gene 















Results for Figure S6 
Heatmaps of cell-subset response probabilities in all subjects from three clinical groups (HIV-IGRA+, 
HIV+IGRA+ and HIV-IGRA-) studied for EC- and LT Ag-specific CD4+ T-cell responses were generated 
by COMPASS analysis (Figure S6). We observed that single-positive cells expressing IFN-γ, TNF-α 
and Th17 (IL-17A, IL-17F and IL-22) cytokines mostly remained unchanged, with an increase only in 
IL-2+ cells; however, MIP-1β and IL-10 single-positive cells were drastically reduced in HIV+IGRA+ 
compared to HIV-IGRA+ subjects in response to EC stimulation. CD4+ subsets expressing TNF-α in 
combination with IL-2, MIP-1β, IL-10 or IL-22 as well as IL-10+IL-17F+ were markedly reduced in 
HIV+IGRA+ vs. HIV-IGRA+ subjects. We also observed a slight decrease of 4+ (IFN-γ+IL-2+TNF-α+MIP-
1β+) CD4+ T-cell subset, however, no significant changes were observed in the probability of 3+ subset 
(IFN-γ+IL-2+TNF-α+) between the HIV-IGRA+ and HIV+IGRA+ subjects (Figure S6). Interestingly, there 
was a profound impairment in the polyfunctional response to LT Ag stimulation compared to EC, with 
HIV-infected IGRA+ subjects having relatively smaller proportion of cells that express a combination of 
2, 3, 4 and 5 cytokines, compared with HIV-uninfected IGRA+ subjects. The analysis also revealed that 
IFN-γ+IL-2+ as well as dual subsets producing MIP-1β or IL-10 in combination with Th17 cytokines to 
be most significantly reduced. Within subsets that expressed 3, 4, or 5 cytokines, HIV infection 
considerably decreased subsets that predominantly expressed TNF-α and/or Th17 cytokines in 
combination with IL-10, although the probability of IFN-γ+IL-2+TNF-α+ subset remained unchanged. No 
significant differences between HIV-infected and HIV-uninfected individuals were detected in the 
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